2014 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
08/12/14Seattle Genetics Initiates Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
-Sixth Proprietary ADC in Clinical Development for the Treatment of Cancer- -Second Proprietary ADC Program Utilizing Newest ADC Technology to Advance into Clinical Trials- BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 12, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced the initiation of a phase 1 clinical trial evaluating SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell... 
Printer Friendly Version
07/31/14Seattle Genetics Reports Second Quarter 2014 Financial Results
-Total Second Quarter Revenues of $68.3 Million, Including $44.8 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -ADCETRIS 2014 Net Sales Guidance Increased to a Range of $160 million to $170 million- -ADCETRIS Phase 3 AETHERA Clinical Trial Top-Line Data to be Reported by October 2014- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 31, 2014-- Se... 
Printer Friendly Version
07/09/14Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2014 Financial Results on July 31, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 9, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2014 financial results on Thursday, July 31, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access o... 
Printer Friendly Version
06/01/14Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting
CHICAGO--(BUSINESS WIRE)--Jun. 1, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today will present interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. SGN-CD19A is an ADC targeting CD19, a protein expressed on B-cell malignancies. “... 
Printer Friendly Version
05/31/14Seattle Genetics Highlights Data from Multiple Collaborator Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting
-AbbVie Presents First Phase 1 Data Evaluating Novel ADC Candidate ABT-414 in Glioblastoma- -Genentech Presents Preliminary Phase 2 Results Evaluating Two ADC Candidates, Polatuzumab Vedotin and Pinatuzumab Vedotin, in Relapsed/Refractory Non-Hodgkin Lymphoma- CHICAGO--(BUSINESS WIRE)--May 31, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from several collaborator antibody-drug conjugate (ADC) programs present... 
Printer Friendly Version
05/29/14Seattle Genetics to Present at Jefferies Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--May 29, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Jefferies Global Healthcare Conference on Tuesday, June 3, 2014, at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattle Genetics is ... 
Printer Friendly Version
05/14/14Seattle Genetics and Collaborators Will Present Data from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--May 14, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. With over 16 years of experience and knowledge in ADC innovation, Seattle Genetics is the leader in ... 
Printer Friendly Version
05/07/14Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May 7, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.   Bank of America Merrill ... 
Printer Friendly Version
05/01/14Seattle Genetics Reports First Quarter 2014 Financial Results
-Total First Quarter Revenues of $68.3 Million, Including $38.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--May 1, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2014. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical ... 
Printer Friendly Version
04/16/14Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 16, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on... 
Printer Friendly Version
04/08/14Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS® (Brentuximab Vedotin) in Key Countries
$6 Million in Milestone Payments Triggered by Achieving First Commercial Sales of ADCETRIS in Australia, South Korea and Mexico for Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 8, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result... 
Printer Friendly Version
04/07/14Seattle Genetics Highlights Antibody-Drug Conjugate (ADC) Program and Technology Advances at AACR
-Seattle Genetics’ ADC Technology Featured in More Than 15 Presentations- -Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 7, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meetin... 
Printer Friendly Version
02/27/14Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings
-Interim Data Demonstrate 92 Percent Objective Response Rate in Ongoing Phase 1/2 Clinical Trial Evaluating ADCETRIS in Combination with Bendamustine for the Treatment of Salvage Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data at the 2014 Bone Marrow Transplant (BMT) Tandem Meetings being held February 26 to March 2, 2014, in Dallas, T... 
Printer Friendly Version
02/11/14Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results
-Total 2013 Revenues of $269.3 Million, Including $144.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Data Anticipated in 2014 from ADCETRIS Phase 3 AETHERA Trial and SGN-CD19A and SGN-CD33A Pipeline Programs- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 11, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quart... 
Printer Friendly Version
02/10/14Seattle Genetics Announces Executive Promotions and Management Addition
-Commercial Leadership Promotions for Chris Boerner to Executive Vice President, Commercial and Charles Romp to Senior Vice President, Sales- -Legal Group Promotions for Kirk Schumacher to Senior Vice President, Legal Affairs and Compliance and General Counsel and Mark Sandbaken to Vice President, Intellectual Property- -David Fontana Named Vice President, Portfolio and Program Management and ADCETRIS® (Brentuximab Vedotin) Program ... 
Printer Friendly Version
02/06/14Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 6, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Leerink Swann Global Healthcare Conference ... 
Printer Friendly Version
02/05/14Seattle Genetics Achieves Sales Milestone Under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda
-$5 million milestone payment triggered by annual ADCETRIS net sales exceeding $100 million in Takeda territories- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 5, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN), today announced that it will receive a $5 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda). The milestone was triggered by Takeda surpassing annual ADCETRIS net ... 
Printer Friendly Version
01/23/14Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2013 Financial Results on February 11, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 23, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2013 financial results on Tuesday, February 11, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/17/14Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
- New Drug Approval of ADCETRIS will Trigger Milestone Payments to Seattle Genetics Totaling $9 Million Upon Final Pricing Agreement in Japan - BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 17, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare (MHLW) fo... 
Printer Friendly Version
01/13/14Seattle Genetics Highlights Key 2014 Milestones and Activities at J.P. Morgan Healthcare Conference
- Phase 3 ADCETRIS® (Brentuximab Vedotin) AETHERA Study Data to be Reported in the Second Half of 2014 - - Data Presentations Anticipated in 2014 from a Broad Portfolio of Antibody-Drug Conjugate Programs, including ADCETRIS, SGN-CD19A and SGN-CD33A - BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted several anticipated 2014 milestones related to ADCETRIS (brentuximab vedoti... 
Printer Friendly Version
01/13/14Seattle Genetics Appoints John A. Orwin to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that John A. Orwin has been appointed to the company’s Board of Directors. Mr. Orwin is a biotechnology and pharmaceutical industry veteran with nearly 25 years of experience, including senior leadership positions in many commercial oncology organizations. He currently serves as Chief Executive Officer of Relypsa, a clinical-stage pharmaceutical company.... 
Printer Friendly Version
01/08/14Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 8, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has further expanded its antibody-drug conjugate (ADC) collaboration with AbbVie (NYSE: ABBV). Under the expanded deal, AbbVie will pay an upfront fee of $25 million for additional rights to utilize Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets, including access to Seattle Genetics’ pyrrolobenzodiazepine ... 
Printer Friendly Version
01/06/14Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 9:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version